PLOD2, a key factor for MRL MSC metabolism and chondroprotective properties
Sarah Bahraoui(Inserm), Farida Djouad(Inserm), François Autelitano(Evotec (Germany)), Christian Jørgensen(Inserm), Mingxing Wei, Gautier Téjédor(Inserm), Anne-Laure Mausset-Bonnefont(Inserm)
Cited by 1
Related Papers
Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial
|Stem Cells Translational Medicine|2016|493
Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid
|Arthritis & Rheumatism|2012|168
Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis
|Annals of the Rheumatic Diseases|2007|154
Glucocorticoid‐induced leucine zipper is an endogenous antiinflammatory mediator in arthritis
|Arthritis & Rheumatism|2010|85